Korea Exchange · Healthcare
Ildong Holdings stock from India: price, numbers and tax
Ildong Holdings (000230) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Ildong Holdings at a glance
- Price
- ₩6,160.00-₩110.00 (1.75%)
- Market cap
- ₩71.09B
- Day range
- ₩6,070.00 – ₩6,290.00
- P/E
- 2.32
- Dividend yield
- 1.62%
- Volume
- 6.36K
- 1 month
- -0.81%
- 6 months
- -37.14%
- YTD
- -53.65%
- 1 year
- -40.19%
- 5 years
- -51.69%
Ildong Holdings statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩590.9B | ₩657.6B | ₩638.4B | ₩675.5B | ₩592.4B |
| Gross profit | ₩215.1B | ₩232.8B | ₩198.9B | ₩239.1B | ₩220.8B |
| Operating income | ₩12.1B | −₩2.4B | −₩79.6B | −₩98.3B | −₩81.7B |
| Net income | ₩10.9B | ₩63.0B | −₩59.6B | −₩102.4B | −₩70.9B |
| Earnings per share | ₩966.78 | ₩5,582.50 | −₩5,276.86 | −₩9,064.10 | −₩6,277.90 |
| EBITDA | ₩41.5B | ₩124.4B | −₩64.0B | −₩116.3B | −₩41.7B |
| Total assets | ₩802.9B | ₩854.7B | ₩877.0B | ₩862.6B | ₩920.8B |
| Total debt | ₩217.0B | ₩324.8B | ₩325.4B | ₩299.1B | ₩324.1B |
| Cash and short-term investments | ₩77.8B | ₩94.6B | ₩102.5B | ₩136.4B | ₩200.8B |
| Shareholders' equity | ₩168.8B | ₩133.9B | ₩39.0B | ₩11.8B | ₩53.3B |
| Operating cash flow | ₩26.9B | ₩17.3B | −₩57.8B | −₩74.6B | −₩30.5B |
| Free cash flow | ₩12.8B | ₩1.7B | −₩77.3B | −₩95.7B | −₩53.3B |
| Capital expenditure | −₩14.0B | −₩15.6B | −₩19.5B | −₩21.1B | −₩22.7B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Yuhan | 000100.KS | ₩73,100.00 | ₩5.38T |
| Dong-A Socio | 000640.KS | ₩93,000.00 | ₩626.13B |
| Ildong Pharmaceutical | 249420.KS | ₩14,020.00 | ₩441.74B |
| Samil Pharmaceutical | 000520.KS | ₩8,350.00 | ₩178.44B |
| Ilsung Is | 003120.KS | ₩22,350.00 | ₩160.07B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| CanSino Biologics | 6185.HK | HK$35.02 | HK$12.26B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Ildong Holdings from India
What Ildong Holdings does
Ildong Holdings Co., Ltd., established in Seoul, South Korea, in 1941, operates internationally, specializing in the innovation, production, and supply of pharmaceutical goods. The company actively researches and develops novel therapeutics for challenging conditions such as resistant bacteria, various cancers, Alzheimer's disease, obesity, and age-related ailments. Ildong Holdings operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Ildong Holdings shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.